Fuhai Hui1, Yingshi Zhang1, Tianshu Ren1,2, Xiang Li1,2, Mingyi Zhao3, Qingchun Zhao4,5. 1. Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, 110016, People's Republic of China. 2. Department of Pharmacy, Northern Theater Command General Hospital, Shenyang, 110840, People's Republic of China. 3. Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, 110016, People's Republic of China. zmy_dl@126.com. 4. Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, 110016, People's Republic of China. zhaoqingchun1967@163.com. 5. Department of Pharmacy, Northern Theater Command General Hospital, Shenyang, 110840, People's Republic of China. zhaoqingchun1967@163.com.
Abstract
PURPOSE: Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta-analysis and to identify the most suitable dosage and intervention period for using metformin in adolescents and adults. METHODS: We searched databases for studies published by April 2018. A total of 34 trials (44 analyses) involving 8461 participants and 16 intervention arms were eligible. The study was registered with PROSPERO International prospective register of systematic reviews (CRD42017081053). RESULTS: Metformin was found to significantly decrease body mass index percentile (BMI) and had a tendency to decrease BMI (kg/m2) and weight (kg). Significant efficacy was observed in many subgroups. The metaregression may have identified the causes of heterogeneity as metformin dosage, control type, and intervention period. Network meta-analysis revealed that in adolescents, intervention with 2000 mg/day metformin ranked better than other interventions; however, 1000 mg/day metformin for 3 months may be most suitable for adolescents. For adults, metformin at doses of 3000 and 1000 mg/day ranked the highest, other than minimeal and lifestyle interventions; moreover, intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults. CONCLUSION: When considering the efficacy of interventions for losing weight, metformin offers clear advantages for overweight and obese populations.
PURPOSE: Our aim was to assess the efficacy of metformin for weight loss in overweight and obesepeople through a systematic review and network meta-analysis and to identify the most suitable dosage and intervention period for using metformin in adolescents and adults. METHODS: We searched databases for studies published by April 2018. A total of 34 trials (44 analyses) involving 8461 participants and 16 intervention arms were eligible. The study was registered with PROSPERO International prospective register of systematic reviews (CRD42017081053). RESULTS:Metformin was found to significantly decrease body mass index percentile (BMI) and had a tendency to decrease BMI (kg/m2) and weight (kg). Significant efficacy was observed in many subgroups. The metaregression may have identified the causes of heterogeneity as metformin dosage, control type, and intervention period. Network meta-analysis revealed that in adolescents, intervention with 2000 mg/day metformin ranked better than other interventions; however, 1000 mg/day metformin for 3 months may be most suitable for adolescents. For adults, metformin at doses of 3000 and 1000 mg/day ranked the highest, other than minimeal and lifestyle interventions; moreover, intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults. CONCLUSION: When considering the efficacy of interventions for losing weight, metformin offers clear advantages for overweight and obese populations.
Authors: C J Glueck; R N Fontaine; P Wang; M T Subbiah; K Weber; E Illig; P Streicher; L Sieve-Smith; T M Tracy; J E Lang; P McCullough Journal: Metabolism Date: 2001-07 Impact factor: 8.694
Authors: M A Charles; E Eschwège; P Grandmottet; F Isnard; J M Cohen; J L Bensoussan; H Berche; O Chapiro; P André; P Vague; I Juhan-Vague; J M Bard; M Safar Journal: Diabetes Metab Res Rev Date: 2000 Jan-Feb Impact factor: 4.876
Authors: R Pasquali; A Gambineri; D Biscotti; V Vicennati; L Gagliardi; D Colitta; S Fiorini; G E Cognigni; M Filicori; A M Morselli-Labate Journal: J Clin Endocrinol Metab Date: 2000-08 Impact factor: 5.958
Authors: E Mannucci; A Ognibene; F Cremasco; G Bardini; A Mencucci; E Pierazzuoli; S Ciani; G Messeri; C M Rotella Journal: Diabetes Care Date: 2001-03 Impact factor: 19.112
Authors: Sara Cruciani; Giuseppe Garroni; Renzo Pala; Donatella Coradduzza; Maria Laura Cossu; Giorgio Carlo Ginesu; Giampiero Capobianco; Salvatore Dessole; Carlo Ventura; Margherita Maioli Journal: Adipocyte Date: 2022-12 Impact factor: 3.553
Authors: Chantal A Pileggi; Breana G Hooks; Ruth McPherson; Robert R M Dent; Mary-Ellen Harper Journal: Clin Sci (Lond) Date: 2022-07-29 Impact factor: 6.876